# US 2026/0062467 A1 · Single-chain solanezumab antibody-transferrin fusion protein for enhanced efficacy and indications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062467 A1
- Document ID: US20260062467A1
- Status: Published application
- Kind: A1
- Application number: 18/821,862
- Filed: 2024-08-30
- Published: 2026-03-05
- Earliest claimed: 2024-08-30
- Assignees: RNA Therapeutics, Inc.
- Applicants: RNA Therapeutics, Inc.
- Inventors: Matthias Magoola; Sarfaraz K. Niazi
- Web page: https://patentgrep.com/patent/US20260062467A1

## CPC

- C07K 16/18: against material from animals or humans
- C07K 14/79: Transferrins, e.g. lactoferrins, ovotransferrins
- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/50: containing protease site
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The efficacy and indication of solanezumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

## Claims

### Claim 1

A fusion protein comprising a single chain variable fragment (scFv) of solanezumab antibody, conjugated with an N-terminal lobe of transferrin protein (PDB: 1a8e; 22-350 gene PRO1400, TF) using an environment-sensitive cleavable linker or linkers.

### Claim 2 (depends on 1)

The fusion protein of claim 1, wherein the scFv comprises a variable heavy chain (VH) and variable light chain (VL) conjugated using a (G4S)3 linker.

### Claim 3 (depends on 1)

The fusion protein of claim 1, wherein the N-terminal lobe of transferrin is fused to either the carboxyl-terminus or the amino-terminus of the scFv, either monovalently or multivalently.

### Claim 4 (depends on 1)

The fusion protein of claim 1, wherein the cleavable linker is sensitive to pH, redox potential, Cathepsin B or D, or MMP (matrix metalloproteinase)-sensitive, or a combination thereof.

### Claim 5 (depends on 4)

The fusion protein of claim 4, wherein the cleavable linker is GSG-HH-GFLG-GSG GFLG.

### Claim 6 (depends on 1)

The fusion protein of claim 1, wherein the fusion protein is produced using recombinant expression in bacteria or mammalian cells or delivered to the body by encoding through an mRNA composition.